摘要
Abstract
Objective To analyze the influence of recombinant human endostatin combined concurrent chemoradiotherapy on prognosis and malignant degree of nasopharyngeal carcinoma.Methods Seventy-eight cases of nasopharyngeal carcinoma patients in our hospital between November 2012 and January 2015 were chosen as research subjects and divided into observation group (36 cases,received recombinant human Endostatin combined concurrent chemoradiotherapy) and control group (42 cases,received chemoradiotherapy alone).Nasopharyngeal carcinoma prognostic factor protein expression and serum growth factor level and serum disease-associated factor levels were compared between the two groups.Results The expression levels of heparitinase (HPA),CK23,HIF-1α and LMP1 protein in the nasopharyngeal carcinoma specimens of the observation group were lower than those of the control group after treatment (P ＜ 0.05).Serum TGF-β1,PDGF-β,EGF,EGFR and VEGF values in the observation group were lower than those in the control group after treatment (P ＜ 0.05).Serum MTP-3α,α-HBDH,CYFRA21-1,TK1,PC Ⅲ and LN values in the observation group were lower than those in the control group (P ＜ 0.05).Conclusions Recombinant human endostatin combined concurrent chemoradiotherapy can reduce degree of malignancy and improve prognosis in nasopharyngeal carcinoma patients,and has positive significance.关键词
鼻咽癌/重组人血管内皮抑制素/同步放化疗Key words
nasopharyngeal carcinoma/recombinant human endostatin/concurrent chemoradiotherapy分类
医药卫生
